TrioxNano

Company Overview

Snapshot

Founded in July 2015 by Roy Farfara, TrioxNano operates with 1–10 employees. The company has raised $3.6M across two funding rounds. In November 2021, TrioxNano secured seed funding.

Business overview

TrioxNano is a Health Tech & Life Sciences company specializing in programmable medicine through synthetic DNA molecular machines. The company develops a biosphere of therapeutic and diagnostic solutions, including Programmable ADCs (P-ADC) for targeted mRNA knockdown in cancer treatment, Programmable Drug Delivery Platforms (P-DDP) for precise drug delivery, Programmable DNA Strip Technology (P-DST) for at-home antigen testing, and Precision Cancer Profiling using mRNA Knockdown Technology (PCPM) for functional cancer diagnostics. TrioxNano's solutions aim to address market challenges in oncology and diagnostics by improving efficacy, reducing toxicity, and enabling precision medicine across global markets.

Company Intelligence Q&A

What is TrioxNano's core technology?

TrioxNano develops programmable medicine using synthetic DNA molecular machines to create therapeutic and diagnostic solutions.

When was TrioxNano founded?

TrioxNano was founded in July 2015.

Who is the founder of TrioxNano?

Roy Farfara is the founder and CEO of TrioxNano.

What is TrioxNano's status as of December 2024?

TrioxNano ceased to operate in December 2024.

What is the total capital raised by TrioxNano?

TrioxNano has raised a total of $3.6M across two funding rounds.